{
    "clinical_study": {
        "@rank": "141392", 
        "arm_group": [
            {
                "arm_group_label": "Insulin Lispro A", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin Lispro A administered subcutaneously (SC) once in two of four study periods. (Two doses total)."
            }, 
            {
                "arm_group_label": "Insulin Lispro B", 
                "arm_group_type": "Experimental", 
                "description": "Insulin Lispro B administered SC once in two of four study periods. (Two doses total)."
            }
        ], 
        "brief_summary": {
            "textblock": "The study involves 4 injections of insulin and its purpose is to:\n\n        -  Determine if 2 types of insulin lispro are treated by the body in a similar way.\n\n        -  Compare how the 2 types of insulin lispro affect blood sugar level.\n\n        -  Determine the safety of each insulin lispro and any side effects that might be\n           associated with them when given to healthy participants.\n\n      The study is expected to last up to approximately 9 weeks for each participant."
        }, 
        "brief_title": "A Study of 2 Different Forms of Insulin Lispro in Healthy Participants", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are healthy males or females\n\n          -  Body mass index (BMI) between 18.5 and 29.9 kilogram per meter squared (kg/m^2)\n\n          -  Are nonsmokers\n\n          -  Have normal blood pressure and pulse rate, a normal electrocardiogram (ECG), and\n             clinical laboratory test results within normal reference range at screening.\n\n        Exclusion Criteria:\n\n          -  History of first-degree relatives known to have diabetes mellitus\n\n          -  Evidence of significant active neuropsychiatric disease\n\n          -  Evidence of an acute infection with fever or infectious disease\n\n          -  Intend to use over-the-counter or prescription medication (apart from vitamin/mineral\n             supplements, occasional paracetamol, or birth control methods).\n\n          -  Have used systemic glucocorticoids within 3 months prior to entry into the study.\n\n          -  Have donated blood of 1 unit or more within the last 3 months prior to study entry\n\n          -  Excessive alcohol intake\n\n          -  Have a fasting venous blood glucose (fasting blood glucose [FBG], plasma) >6\n             millimoles per liter (mmol/L) at screening\n\n          -  Have positive hepatitis B surface antigen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111083", 
            "org_study_id": "15418", 
            "secondary_id": "F3Z-EW-IOQM"
        }, 
        "intervention": {
            "arm_group_label": [
                "Insulin Lispro A", 
                "Insulin Lispro B"
            ], 
            "description": "LY275585 administered SC.", 
            "intervention_name": "Insulin Lispro", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "117597"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Serum Insulin Concentration versus Time Curve From Zero to Time of Return to Baseline (AUC0-tlast) for Insulin Lispro A versus Insulin Lispro B", 
                "safety_issue": "No", 
                "time_frame": "Day 1, predose through 8 hours post dose in each period."
            }, 
            {
                "measure": "Maximum Serum Insulin Concentration (Cmax) for Insulin Lispro A versus Insulin Lispro B", 
                "safety_issue": "No", 
                "time_frame": "Day 1, predose through 8 hours post dose in each period"
            }, 
            {
                "measure": "Time of Maximum Observed Serum Concentration (tmax) for Insulin Lispro A versus Insulin Lispro B.", 
                "safety_issue": "No", 
                "time_frame": "Day 1, predose through 8 hours post dose in each period."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111083"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total Amount of Glucose Infused (Gtot) for Insulin Lispro A versus Insulin Lispro B", 
                "safety_issue": "No", 
                "time_frame": "Day1, predose through 8 hours post dose in each period."
            }, 
            {
                "measure": "Maximum Glucose Infusion Rate (Rmax) for Insulin Lispro A versus Insulin Lispro B", 
                "safety_issue": "No", 
                "time_frame": "Day 1, predose through 8 hours post dose in each period."
            }, 
            {
                "measure": "Time of Maximum Glucose Infusion Rate (tRmax) for Insulin Lispro A versus Insulin Lispro B", 
                "safety_issue": "No", 
                "time_frame": "Day 1, predose through 8 hours post dose in each period."
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}